Patent application number | Description | Published |
20080292679 | BIODEGRADABLE DRUG DELIVERY SYSTEM - A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics. | 11-27-2008 |
20090004244 | Iris design as a drug depot for zonal drug delivery by contact lens - A contact lens providing zonal drug delivery includes a lens body having an optical axis and an opaque simulated iris pattern applied to the lens body, about the optical axis, with the pattern including an ophthalmic drug. | 01-01-2009 |
20090004245 | Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens - A drug delivery device includes a contact lens along with a drug delivery zone disposed above an applied axis of the lens. A colored layer is disposed over the drug delivery zone in order to mark a color of the drug delivery zone. | 01-01-2009 |
20090118703 | DRUG DELIVERY SYSTEMS AND METHODS - A delivery system includes a housing along with a tip connected to one end of the housing. A first cannula extending from the tip is provided for inserting a rod implant into tissue. A second cannula, concentrically disposed within the first cannula, is utilized to force the rod implant from the first cannula and for ejecting a fluid behind the inserted rod implant in the tissue. | 05-07-2009 |
20100015158 | METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION - Compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA). | 01-21-2010 |
20100098772 | DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING NEOVASCULARIZATION - Anti-angiogenesis compositions, and methods of using such compositions, useful for intraocular to treat neovascularization. The compositions can have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps. | 04-22-2010 |
20100247606 | INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS - Biocompatible, bioerodible sustained release implants and microspheres for intracameral or anterior vitreal placement include an anti-hypertensive agent and a biodegradable polymer effective to treat an ocular hypertensive condition (such as glaucoma) by relapsing therapeutic amount of the anti-hypertensive agent over a period of time between | 09-30-2010 |
20110182966 | INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS - Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye. | 07-28-2011 |
20120142652 | COMPOSITIONS AND METHODS FOR LOCALIZED THERAPY OF THE EYE - Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers. | 06-07-2012 |
20120245505 | INTRACAMERAL DEVICES FOR SUSTAINED DELIVERY - Described herein are intracameral drug and/or therapeutic bioactive agent delivery devices comprising a substantially cylindrical structure for at least partial placement into the anterior chamber of an eye The intracameral delivery devices have a sustained release material associated with at least a portion of the device and at least one drug and/or therapeutic bioactive agent associated with said sustained release material. | 09-27-2012 |
20120263779 | BIODEGRADABLE DRUG DELIVERY SYSTEM - A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics. | 10-18-2012 |
20130017243 | SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY - The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days. | 01-17-2013 |
20130046003 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-BROMO-N-(IMIDAZOLIDIN-2-YLIDENE)-1H-BENZIMIDAZOL-5-AMINE FOR TREATING RETINAL DISEASES - The present invention relates to a method for treating retinal diseases and a method for retinal neuroprotection, in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine or pharmaceutically acceptable salts thereof. | 02-21-2013 |
20130096534 | Drug Delivery Systems and Methods - A delivery system includes a housing along with a tip connected to one end of the housing. A first cannula extending from the tip is provided for inserting a rod implant into tissue. A second cannula, concentrically disposed within the first cannula, is utilized to force the rod implant from the first cannula and for ejecting a fluid behind the inserted rod implant in the tissue. | 04-18-2013 |
20130236526 | Sustained Release Intraocular Implants and Methods for Preventing Retinal Dysfunction - Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like. | 09-12-2013 |
20140031298 | Compositions and Methods for Localized Therapy of the Eye - Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers. | 01-30-2014 |
20140038972 | ALPHA-2 AGONIST POLYMERIC DRUG DELIVERY SYSTEMS - Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure. | 02-06-2014 |
20140045945 | INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS - Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye. | 02-13-2014 |
20140086974 | BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR THE SUSTAINED RELEASE OF PROTEINS - Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye. | 03-27-2014 |
20140322206 | METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION - Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA). | 10-30-2014 |